Finance Watch: ARCH Raises $1.85bn Venture Fund To Back Early-Stage Companies

Design Therapeutics Raises $125m, TScan Brings In $100m

Private Company Edition: The venture capital firm said it will back biopharma, diagnostics and other opportunities in health care. In addition to the Design and TScan mega-rounds, Verve raised $94m, Vera garnered $80m and Ixaka (formerly Rexgenero) closed a £40m ($54.7m) financing. 

Finance Watch

ARCH Venture Partners raised its largest venture capital fund yet, the $1.85bn ARCH Venture Fund XI, which it plans to invest in a range of biotechnology opportunities, including drug developers focused on infectious disease, mental health, immunology, oncology and neurology.

The VC firm, which closed two funds totaling $1.1bn in April, said on 28 January that it will also invest...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.